These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19946342)

  • 1. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT.
    Egger SS; Meier S; Leu C; Christen S; Gratwohl A; Krähenbühl S; Haschke M
    Bone Marrow Transplant; 2010 Jul; 45(7):1197-203. PubMed ID: 19946342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
    Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
    Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.
    Verma A; Williams S; Trifilio S; Zembower T; Mehta J
    Bone Marrow Transplant; 2004 May; 33(10):1065-6. PubMed ID: 15048146
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
    Pagano L; Valentini CG; Fianchi L; Caira M
    J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.
    Baddley JW; Andes DR; Marr KA; Kauffman CA; Kontoyiannis DP; Ito JI; Schuster MG; Brizendine KD; Patterson TF; Lyon GM; Boeckh M; Oster RA; Chiller T; Pappas PG
    Med Mycol; 2013 Feb; 51(2):128-35. PubMed ID: 22680976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
    Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
    Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antifungal therapy for invasive aspergillosis.
    Cesaro S; Visintin G
    Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
    [No Abstract]   [Full Text] [Related]  

  • 14. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
    Selleslag D; Vogelaers D; Marbaix S
    Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antifungal therapy for invasive aspergillosis.
    Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
    Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.
    Hol JA; Wolfs TF; Bierings MB; Lindemans CA; Versluys AB; Wildt de A; Gerhardt CE; Boelens JJ
    Bone Marrow Transplant; 2014 Jan; 49(1):95-101. PubMed ID: 24121212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.
    Kulemann V; Bauer M; Graninger W; Joukhadar C
    Pharmacology; 2005 Dec; 75(4):165-78. PubMed ID: 16192747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
    Kullberg BJ; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Rex JH; Cleary JD; Rubinstein E; Church LW; Brown JM; Schlamm HT; Oborska IT; Hilton F; Hodges MR
    Lancet; 2005 Oct 22-28; 366(9495):1435-42. PubMed ID: 16243088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.